Adam J. Wolpaw

Aug 20, 2024 | nature.com | Guillem Pascual-Pasto |Kathrin Bernt |Adam J. Wolpaw |Dimiter S. Dimitrov |Brendan McIntyre |Anna M. Giudice

AbstractNovel chimeric antigen receptor (CAR) T-cell approaches are needed to improve therapeutic efficacy in solid tumors. High-risk neuroblastoma is an aggressive pediatric solid tumor that expresses cell-surface GPC2 and GD2 with a tumor microenvironment infiltrated by CD16a-expressing innate immune cells. Here we engineer T-cells to express a GPC2-directed CAR and simultaneously secrete a bispecific innate immune cell engager (BiCE) targeting both GD2 and CD16a.

Oct 26, 2023 | ascopubs.org | Adam J. Wolpaw

Pathways Involved in the Effect of Eflornithine in NeuroblastomaThe following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript.